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Functional brain activation changes
associated with practice in delaying
smoking among moderate to heavy
smokers: study protocol and rationale of a
randomized trial (COPE)
Andrew T. Fox1 , Delwyn Catley2, Kimber P. Richter3, Edward F. Ellerbeck3, Morgan G. Brucks1,
Vlad B. Papa1 and Laura E. Martin1,3*

Abstract
Background: Most smokers struggle to overcome tobacco addiction. Neuroscientific models of addiction
emphasize the importance of brain regions associated with cognitive control and reward to understand the cycle
of addiction and relapse. During an attempt at abstinence, the cognitive control system appears to be
underpowered to override the heightened reward system of the addicted brain. Thus, one neural target for
treatment is to strengthen the cognitive control system. It may be possible to improve the functioning of the
cognitive control system via deliberate practice.
Methods/design: This study will determine the effects of practicing delaying smoking on brain and behavioral
measures of cognitive control. Smoking patterns will be monitored for 1 week and then smokers (N = 80) will be
randomized to either practice cognitive control by delaying their first cigarette of the day for 2 weeks (practice
group) or they will continue monitoring only (no practice group). Functional magnetic resonance imaging will be
performed while smokers regulate their responses to smoking images (i) at baseline and (ii) after 2 weeks of
practice (or no practice).
Discussion: The primary aim of this study will be to identify the impact of practicing cognitive control on
functional brain activation changes in response to smoking cues. If successful, this project will establish a
neurobiological biomarker for increasing cognitive control and demonstrate the feasibility of neuroimaging
methods to predict the efficacy of an intervention without a large clinical trial.
Trial Registration: ClinicalTrials.gov, NCT03080844. Registered March 15, 2017
Keywords: Smoking, Functional magnetic resonance imaging, Randomized trial, Study protocol
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Background
Thirty-six million American adults smoke cigarettes [1]
despite the known negative consequences [2]: nicotine
addiction is difficult to overcome. Dual-system models
of addiction assert primary roles for two systems: the
cognitive control network (dorsolateral (dlPFC), dorsomedial, and ventrolateral prefrontal cortices [3–5])
and the reward network (ventromedial (vmPFC) and
medial prefrontal cortices, and striatal regions [3–5]). In
addiction, the cognitive control network is considered
underactive while the reward network is considered
overactive [3–6], resulting in a reward network that
overrides the cognitive control network leading to relapse during quit attempts [4, 5, 7, 8].
An important implication of these models is that
pharmacotherapy and/or behavioral treatments for
smoking cessation should ideally target both systems to
improve outcomes [4, 5]. There is evidence that bupropion and varenicline reduce activation in the reward network [9–12], but there is little evidence for any
interventions that impact the cognitive control network.
Cognitive-behavioral smoking cessation treatment commonly involves identifying and altering smoking cues
(triggers), self-monitoring, and cognitive restructuring
[13]. In clinical practice, smokers are encouraged to develop a quit plan whereby they self-administer these
techniques to resist cravings and maintain abstinence
[13, 14]. Counseling patients to use these techniques
after they quit significantly improves cessation rates [15];
however, it is unclear whether using these techniques
impacts either the cognitive control or reward networks.
Although the neural impact of behavioral cessation
treatment is unknown, evidence from research on cognitive behavioral therapy (CBT) for depression indicates
that practicing behavioral strategies can impact cognitive
control areas [16, 17]. This suggests that cognitive control practice could enhance smokers’ ability to resist
cravings and improve success at maintaining abstinence.
If true, this would have important treatment implications because current behavioral treatment does not routinely implement practicing behavioral strategies prior to
making a quit attempt. Emphasizing cognitive control
practice prior to quitting could theoretically improve the
effectiveness of cessation by enhancing smokers’ cognitive control capacity.
The purpose of this study is to examine among
smokers the effect of cognitive control practice on
cognitive control brain activation during efforts to
regulate craving. Brain activation can be measured
non-invasively using functional magnetic resonance
imaging (fMRI) while smokers view smoking cues or
images that trigger cravings [18–21]. Greater efforts
to regulate craving (i.e., exerting cognitive control)
have been linked to greater activation of the dlPFC
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[15], which is implicated in the cognitive control network [14]. In this study, participants will be randomized to 2 weeks of practice in exerting cognitive
control by delaying the first cigarette of the day or
smoking as usual; the comparison group will monitor
their smoking behavior but will not be asked to delay
smoking cigarettes. This study will identify whether:
(i) cognitive control practice leads to changes in brain
activation, (ii) associations exist between the amount
of practice and brain activation changes, and (iii) individual differences in practice relate to brain activation changes. This will enhance our understanding of
treatment mechanisms and provide a model for
studying the impact of behavioral interventions on
brain function.
Study objectives
Primary objective

The primary objective is to identify the impact of practicing compared to not practicing delaying smoking on
functional brain activation changes in the cognitive
control networks in response to smoking cues. We
hypothesize that practice vs. no practice will lead to
greater brain activation increases in the cognitive control network when comparing pre- to post-intervention.
Secondary objective

In the group practicing delaying smoking, the secondary objective is to examine the association between the
amount of practice (i.e., the amount of time the first
cigarette of the day is delayed) and functional brain activation changes in the cognitive control network in response to smoking cues. We hypothesize that greater
levels of practice will correspond to greater brain activation increases in the cognitive control network when
comparing pre- to post-intervention.
Other objectives

Additional objectives are to examine the association between practice-related brain activation changes in the
cognitive control network and individual differences
(e.g., nicotine dependence, motivation, and sex). We
hypothesize that practice-related increases in brain activation in the cognitive control network are expected to
be greatest among more dependent and less motivated
smokers as well as women.

Methods/design
Study overview

We will use a randomized design (parallel group,
two-arm, superiority trial with a 1:1 allocation ratio) to
examine the impact of practicing delaying the first
cigarette of the day on cognitive control brain networks
during an fMRI cue-reactivity task (see Fig. 1). Smokers
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Fig. 1 Flow chart of enrollment, interventions, and assessments

(N = 80) will receive tips on how to resist the urge and
control cravings to smoke and then be randomized either to practice progressively delaying their first cigarette
of the day over a 2-week period (practice) or not to
practice delaying their first cigarette and smoke as usual
over a 2-week period (no practice). Portable carbon
monoxide (CO) monitors will be used to assess objectively the timing of the first and second cigarettes of the
day (days 1–7) and subsequently to monitor practice adherence (i.e., the delay of the first cigarette of the day;
days 8–21). All participants will be given brief advice on
techniques to help them control urges to smoke
based on cognitive behavioral therapy (CBT) techniques. Participants will continue monitoring their
smoking behavior regardless of group assignment. At
baseline (day 7) and following 2 weeks of practice (day
21), participants in both arms will complete an fMRI
session during which they view smoking and food cues
and are asked to rate how much they want them. All
study procedures will be conducted in accordance with
the Code of Ethics of the World Medical Association
(Declaration of Helsinki) and have been approved by the
Institutional Review Board of the University of Kansas
(protocol STUDY00004095). This experiment is registered at ClinicalTrials.gov (NCT03080844).
Design justification

Our reason for delaying the first cigarette of the day as a
way to operationalize practice is based on theoretical

and practical considerations. The first cigarette of the
day is typically one of the most preferred cigarettes of
the day, as smokers replenish nicotine levels depleted
during sleep. Time to first cigarette of the day is also
used as a proxy for level of nicotine dependence [22].
This cigarette is, therefore, an ideal clinical target for
practicing skills for remaining abstinent. It also provides
a practical way to standardize practice in a way that all
participants can implement and it is simple to assess
practice duration. We limited the practice duration to
2 weeks and fMRI assessments to 2, to avoid undue participant burden and to constrain the resources needed
for the project within reasonable limits.
Careful consideration was given to the selection of the
fMRI task for the proposed study. We selected the smoking cue-reactivity task based on findings supporting robust
activations in cognitive control regions (particularly the
dlPFC) [23] and based on a wide body of previous neuroimaging studies of smoking showing that cue reactivity
can activate the cognitive control networks [18–21, 24].
Analysis plan

The planned data analyses are built around three specific aims. The first aim is to compare changes in brain
activation in cognitive control regions as a result of
cognitive control practice. The second aim is to determine the effect of adherence to the practice regimen on
changes in brain activation in cognitive control regions.
The third aim is to explore the effects of individual
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differences (e.g., level of tobacco dependence, motivation, and sex) on changes in brain activation in cognitive control regions.

self-report measures of impulsivity, and behavioral measures of executive function, decision-making, inhibition,
and demand on changes in cognitive control.

Aim 1 Our primary aim is to identify the impact of
practicing delaying the first cigarette of the day compared to not practicing on functional brain activation
changes in cognitive control regions. The percentage signal change when comparing the negative smoke condition to the positive smoke condition will be computed
for our a priori cognitive control region of interest (ROI)
(i.e., dlPFC) for each subject at each time point and entered into a two-way mixed-effects ANOVA model using
the group (practice, no practice) × time (pre, post) interaction. We hypothesize that practice vs. no practice will
lead to greater pre-to-post brain activation increases in
the cognitive control network.

Power and sample size

Aim 2 We will also identify the impact of adherence to
practicing delaying cigarettes on functional brain activation changes in the cognitive control networks in response to smoking cues. Using only participants from
the practice group, we will calculate Pearson correlations
between differences in brain activation from the negative
smoke and positive smoke conditions and amount of
practice completed. Brain activation will be computed as
percentage signal change from pre- to post-treatment in
response to smoking cues in the a priori dlPFC ROI.
Practice will be quantified as the proportion of time delayed from their usual first cigarette of the day to their
second cigarette of the day and subjectively measured by
participants’ perceived difficulty in delaying the first
cigarette of the day. We hypothesize that greater levels
of practice will show greater brain activation increases in
the cognitive control network in response to negative
smoke compared to positive smoke conditions from preto post-intervention.
Aim 3 (exploratory) Finally, we will examine the association between practice-related brain activation changes
in the cognitive control and reward networks and individual differences (e.g., dependence, motivation, gender,
self-report measures of impulsivity, and behavioral measures of cognitive control). We will perform Pearson correlation analyses to examine the relationship between
dlPFC brain activation changes (i.e., the percentage signal
change in response to negative smoke compared to positive smoke conditions from pre- to post-treatment) and
motivation to quit smoking, nicotine dependence, personality and psychological variables, and cognitive performance. In addition, we will use t-tests to examine gender
differences in brain activation changes. Finally, we will use
multiple regression to explore the effects of gender,
marijuana use, motivation to quit smoking, dependence,

The sample size was based on aim 1 and calculated based
on changes in brain activation observed in pilot data following 1 week of practicing CBT skills and 2 weeks of
CBT sessions. Assuming the no practice group will have a
mean of 0 change in brain activation between day 7 and
day 21, and equal variance in the two groups, our preliminary data suggest Cohen’s d effect sizes of 2.77 and 3.70
for dlPFC and vmPFC, respectively. These effect sizes suggest n = 5 and 4 subjects per group are required to achieve
80% power at 0.05/2 = 0.025 significance level (Bonferroni
correction needed to compensate for tests involving each
of two brain regions) in a two-sided two-sample t-test.
However, the small sample in our pilot data (N = 6) also
indicates wide 95% confidence intervals. Using the conservative estimates of the lower bound of the mean and
upper bound of the standard deviation, the effect sizes are
(0.0991/0.1415) = 0.70 and (0.2037/0.1889) = 1.08. Using a
sample size of n = 40 per group provides 79% and > 99%
power for dlPFC and vmPFC, respectively; the power will
be greater if the actual effect sizes are larger than the conservative estimates.
Participants
Inclusion

Individuals will be eligible if they meet all of the following criteria:
1. Have smoked ≥10 cigarettes per day for the last
6 months
2. Smoke first cigarette within 90 min after waking
3. Age 18 to 60 years
4. Vision normal or corrected to normal (to ensure
that they can accurately see the images on the
screen and select the appropriate response)
5. Willing to complete all appointments and change
smoking behaviors for 2 weeks
6. Have made no quit attempts or attempts to cut
back in the last 30 days
7. Have no plans to quit in the next 30 days
8. High school graduate or GED.
Exclusion

Individuals will be ineligible if they report any of the
following:
1. Serious medical illness unsuitable for the MRI
scanner based on best clinical judgment
2. Any history or current symptoms of neurologic or
psychiatric disorders except depression, anxiety, or
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attention-deficit disorder/attention-deficit hyperactivity disorder
Currently taking anti-seizure medication
History of concussion
Body mass index >50
Left-handed, due to differences in neural
organization between right-handed and left-handed
individuals
History of alcohol or other substance dependence
or current abuse
Risk for hazard due to magnetic fields, such as
metal in the body due to surgery or an accident
(e.g., a pacemaker, cochlear implants, aneurysm
clips, intravascular stents or coils, spinal shunt,
injury involving bullets, shrapnel or metal
implanted in their body, etc.)
Pregnancy.

Final eligibility will be adjudicated by the principal
investigator.
Recruitment

Smokers will be recruited from the Kansas City metropolitan area (population of 2.3 million) using recruitment methods used successfully in the past, including
the internet (e.g., Craigslist and Facebook), print, and
media advertising (e.g., radio and television spots). Prospective participants will be given a phone number,
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email address, and website URL to contact for screening.
We will also recruit participants from our Clinical
Translational Science Award-sponsored Frontiers registry (NIH UL1TR000001), which is a list of smokers who
have agreed to be contacted for research studies. All
study procedures will take place at the University of
Kansas Medical Center, Kansas City, MO, USA.
Study procedures
Consent appointment (day 0)

Study staff will review consent forms describing study
goals, procedures, risks, and confidentiality with each
participant. Those who consent to participate will be enrolled in the study and given instructions on how to prepare for the baseline session, which will include the first
fMRI assessment and daily monitoring of smoking behaviors (days 1–7). In addition, demographic information (including age, gender, education, and income),
smoking history, and other data will be collected at the
consent appointment. Figure 2 is a full list of questionnaires and tasks administered and the timing of their administration. To promote retention, participants will be
compensated for completing questionnaires (Additional
file 1).
Daily monitoring (days 1–7)

Smoking behaviors will be measured using portable Micro+™ basic Smokerlyzer® CO monitors (coVita, Santa

Fig. 2 Study measures and timing (SPIRIT Figure). Cigs cigarettes, MRI magnetic resonance imaging, QSU Questionnaire of Smoking Urges,
UPPS-P Urgency, Premeditation, Perserverance, Sesation-Seeking, and Positive Urgencey
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Barbara, CA, USA). The CO monitors come with software that records their output, such as CO levels and a
timestamp of each CO measurement. A baseline level
will be collected at the beginning of the consent appointment for comparison with levels at the scanning
appointments. At this appointment, we will also show
participants how to use the CO monitor and instruct
them to use it daily during the study. For 1 week following the initial consent appointment, participants will be
asked to smoke as usual and provide CO levels by blowing into the CO monitor mouthpiece: (1) upon waking,
(2) immediately before smoking the first cigarette of the
day, (3) 5 to 10 min following smoking the first cigarette
of the day, and (4) immediately before smoking the second cigarette of the day. This will provide timestamps
for when participants typically smoke their first and second cigarettes of the day, which will be used as a guide
for how long participants in the practice group will be
asked to delay smoking their first cigarette.
Participants will also complete paper-and-pencil daily
logs recording their first two cigarettes and answering
questions relating to their smoking behavior, such as how
many cigarettes they smoked that day and if a day was
considered typical. Participants will be contacted on days
1 and 3 to see if they are having any difficulty using the
monitor and to address any questions. Participants who
consent to receiving texts will receive text prompts on
days 2 and 4 to remind them to use their CO monitor.
Pre-treatment scan appointment (day 7)

Participants will be asked to smoke as usual on the days
of testing. They will be given an opportunity to smoke
immediately prior to their appointment but not again
until they complete testing (about 3–4 h later). This will
be done to minimize the dampening effect on cue reactivity of smoking expectancy [18, 25], to control for
the time of the last cigarette, and to minimize participant burden. Their height and weight will be measured.
There will be at least a 2-h abstinence period prior to
the MRI scans. During this time, participants will fill out
self-report questionnaires, complete neuropsychological
tests, and will be asked to provide a CO measurement.
Other studies have used similar abstinence periods and
seen expected brain activation patterns to smoking cues
[26–31].
Following the fMRI scan, all participants will receive a
10-min CBT style counseling session in which a trained
counselor will discuss how to cope with smoking urges,
emphasizing problem-solving to overcome difficulties
encountered when practicing delaying the first cigarette
of the day. We will provide these tips to all participants
prior to randomization to control for the influence of
the brief counseling on brain activation changes. Without this control, it would be difficult to identify whether
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brain changes observed in the practice group are due to
the brief counseling session or the daily practice of
delaying the first cigarette. To promote retention and
completion of daily questionnaires, participants will be
compensated at the second visit for their time, for completing the one week of CO measurements
Randomization and blinding

Following the brief counseling, participants will be randomized using a 1:1 allocation ratio to the practice or no
practice arm of the study. Groups will be stratified on
gender and marijuana use to prevent these variables
from confounding treatment effects. Based on previous
recruitment data, we expect a 1:1 ratio of men to women
and a 1:2 ratio of marijuana users to non-marijuana
users. Separate blocked randomization sequences
(www.randomization.com) for each of the four strata will
be used. A person from outside the study team, who will
have no interaction with the participants or the data, will
generate the sequence and reveal the group assignments
prior to building the practice schedule. Staff responsible
for enrolling subjects will not participate in generating
the randomization sequence and will not have specific
knowledge of how it was generated.
Study staff who interact with participants will be blinded
to group membership until after the brief counseling session. They will not be informed of group membership
until it is time to reveal it to the participants. Participants
will not be blinded to group membership because there is
no way to institute the intervention without revealing
group membership.
Intervention (days 8–21)

For 2 weeks following the initial fMRI appointment, CO
levels will be recorded daily by having the participant
blow into the CO monitor mouthpiece upon waking, immediately before smoking the first cigarette of the day, 5
to 10 min following smoking the first cigarette of the
day, and immediately before smoking the second
cigarette of the day. This will provide data on adherence
to delaying or not delaying the first cigarette of the day
as instructed. Participants will receive a follow-up phone
call or text on day 8 to see how the use of the monitor is
working and/or how practicing delaying the first
cigarette of the day is going. In addition, we will address
any participant questions. Participants who consent to
receiving texts will also receive text prompts on days 9,
11, 16, and 18 to remind them to use their CO monitor
and/or ask how practicing delaying the first cigarette of
the day is going.
Practice group Half of the participants will be randomized to the practice group. Data from self-reported typical days from the initial week of monitoring will be
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Table 1 Examples of cognitive control regimens for the practice group
Delay to 1st cigarette calculation

Example for smoker who
smokes 1st cigarette
of the day 5 min after
waking and 2nd cigarette
of the day 60 min later

Example for smoker who
smokes 1st cigarette of
the day 30 min after
waking and 2nd cigarette
of the day 90 min later

Baseline week (days 1–7)

Usual time

5 min

30 min

Day 8

Usual time + 0.33 of usual time to 2nd cigarette

~ 25 min

~ 60 min

Day 9

Usual time + 0.5 of usual time to 2nd cigarette

~ 35 min

~ 75 min

Day 10

Usual time + 0.66 of usual time to 2nd cigarette

~ 45 min

~ 90 min

Day 11

Usual time + 1.00 of usual time to 2nd cigarette

~ 65 min

~ 120 min

Day 12

Usual time + 1.33 of usual time to 2nd cigarette

~ 85 min

~ 150 min

Day 13

Usual time + 1.5 of usual time to 2nd cigarette

~ 95 min

~ 165 min

Days 14–20

Usual time + 1.66 of usual time to 2nd cigarette

~ 105 min

~ 180 min

Day 21 (follow-up fMRI)

Usual time

5 min

30 min

fMRI functional magnetic resonance imaging

averaged to build participants’ schedules (Table 1). To
standardize practice for our experiments, we will ask
smokers to delay their first cigarette of the day on a progressive schedule for 1 week with the goal of delaying
their first cigarette to the time of their usual second
cigarette of the day or later. The maximum delay will be
maintained during the second week for a total of 2 weeks
of practice. On day 14, practice group participants will
be sent a text asking, “On a scale from 1 to 5: 1 = not at
all difficult and 5 = extremely difficult – how difficult
would you say delaying your first cigarette has been the
past two days?” If participants report a 1 or 5 for either
day, they will be sent an adjusted schedule. In the case
of a 1, the following 2 days will continue the progressive
schedule until the delay is 2.33 times the length of the
normal delay. In the case of a 5, participants will be
instructed to revert to the day 12 delay (1.33 times the
normal delay) for the remainder of the practice days. Participants will continue to fill out the paper-and-pencil
daily monitoring log with the addition of questions about
how difficult it was to delay the time to the first cigarette
of the day on a scale of 1 = not at all difficult to 5 =
extremely difficult and what strategies they used to delay
the time to the first cigarette.

No practice group Participants in the no practice arm
will not be instructed to change their smoking behavior
in any way. Instead these participants will be instructed
to smoke their cigarettes as usual over a 2-week period
and to continue monitoring their smoking using the CO
monitor and daily monitoring logs so that the study procedures for both arms are as similar as possible. The
daily monitoring log will have an additional question
asking whether they used CBT techniques at other times
during the day to change or reduce their smoking. We

chose a monitoring-only control arm to isolate the impact on brain activation of practicing skills following
brief advice compared to any disruption in usual smoking behaviors engendered by monitoring itself [32].
Post-treatment scan appointment (day 21)

The post-treatment scan appointment will include the
same self-report, behavioral, and fMRI procedures as the
pre-treatment scan appointment (see Fig. 2). In addition,
participants will complete an end-of-study assessment
and debriefing including open-ended questions about
the difficulty of the intervention, study experiences, and
behavioral techniques employed to delay smoking the
first cigarette of the day. Participants will also be given
an overview of the goals of the study and anticipated
outcomes to encourage engagement in research studies
in the future. To promote retention and completion of
daily questionnaires, participants will be compensated at
the second visit for their time, for completing the 2
weeks of CO measurements (i.e., double the potential
payment for the first week of measurements), and for
returning the CO monitor.
Measures
fMRI assessments

Image acquisition Scanning will be performed on a 3-tesla
Siemens Skyra scanner (Siemens, Erlangen, Germany) fitted
with a 20-channel head and neck coil. Following automated
scout image acquisition and shimming procedures to
optimize field homogeneity, resting state, fMRI task, and
structural scans will be acquired. Resting state scanning parameters will include BOLD sequences of 52 contiguous
slices at a 40° angle to the anterior commissure–posterior
commissure (AC-PC) line (repetition time/echo time [time
repetition (TR)/time echo (TE)] = 3000/25 ms, flip angle =
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90°, field of view = 640 × 640, matrix = 80 × 80, slice thickness = 3 mm, in plane resolution = 2.9 mm, 200 data points).
Task scanning parameters will include gradient echo BOLD
scans (five, one for each run of the craving rating task),
which will be acquired in 43 contiguous oblique axial slices
at a 40° angle (TR/TE = 2500/25 ms, flip angle = 90°, field of
view = 560 × 560 mm, matrix = 80 × 80, slice thickness =
3.0 mm, in-plane resolution = 2.9 × 2.9 mm, 145 data points).
Finally, a T1-weighted structural scan will be completed
(3D MPRAGE sequence, TR/TE = 2300/2.95 ms, flip
angle = 9°, field of view = 253 × 270 mm, matrix =
240 × 256, slice thickness = 1.2 mm, 176 slices). This
scan will be used for Talairach transformation and
coregistration with fMRI data. All participants will be
positioned in the scanner so that the angle of the
AC-PC plane is between 17° and 22° to the scanner coordinate space, ensuring that the 40° slice acquisition
angle is constant for all participants. Preprocessing of resting and task fMRI data will be performed for each participant in AFNI (Medical College of Wisconsin).
Regulation-of-craving cognitive control task During
the ~ 30-min fMRI scan, participants will complete a
regulation-of-craving task closely modeled after Kober et
al. [23] in which they will view smoking and food cues
and will be asked to rate “How much do you want this?”
the items on a scale of 1 to 5 (1 = not at all; 5 = a
lot) after viewing them (see Fig. 3). Smoking cues will include pictures such as people smoking and packs of cigarettes. Food cues will include pictures of appetizing

Fig. 3 Diagram depicting scanner task
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food items such as pizza. All cues have been acquired
from previous smoking and food cue reactivity studies
[20, 23, 33, 34] and stock photography websites. Participants will receive instructions to regulate their responses
to these images at the start of each trial. Half of the trials
will be positive trials and half will be negative trials. In
positive trials, participants will be instructed to think
about the positive consequences of consuming the presented item. In negative trials, participants will be
instructed to think about the negative consequences of consuming the presented item. A practice session will be conducted outside the scanner immediately prior to the scan
to ensure that the participants understand the task. Following the imaging session, participants will be asked to describe the strategies they used during the task. Scanning
will be done in five runs of 20 trials each (100 total trials),
with trials of each of the four possible types—positive
smoking, positive food, negative smoking, and negative
food—presented in pseudorandom order. Participants will
see different stimuli sets at each MRI appointment, which
will be counterbalanced across participants. Stimuli will be
presented using E-Prime 3 (Psychology Software Tools).
Optimal timing of stimuli will be estimated using the Analysis of Functional Neuroimages (AFNI) stimulus timing
program (make_random_timing.py).
Regulation-of-craving task data preprocessing The
fMRI images will be realigned to the third slice collected
in each scanning session to correct for motion. The images will be spatially smoothed with a 4-mm full width at
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half maximum (FWHM) Gaussian blur. Timepoints during which participants move more than 0.3 mm within a
TR will be censored. Functional and anatomic images obtained within each session will be aligned and normalized
to Talairach and Tournoux’s [35] stereotaxic atlas. Regressors representing the experimental conditions of interest
(i.e., positive smoke, negative smoke, positive food, and
negative food) will be modeled with a block response
function and entered into the multiple-regression analysis
using a random-effects model. Motion parameters will be
included as nuisance regressors.
The primary contrast of interest will be negative smoke
minus positive smoke, which represents an analog of the
exertion of cognitive control minus general brain activation
engendered by attending to smoking cues. The primary
outcome analysis will focus on the a priori ROI, the dlPFC.
In addition, an exploratory whole-brain analysis will be
used to identify regions outside the dlPFC cognitive control
network that may change with practice (e.g., the insula).
The dlPFC ROI has been selected based on previous studies
[5, 23, 24, 36]. The dlPFC will be defined using anatomical
masks for the dlPFC based on the superior frontal gyrus
and the middle frontal gyrus regions identified by AFNI’s
whereami function. Multiple comparisons will be corrected
using a familywise approach in which clusters will be considered significant at pvoxelwise < .01 and pcorrected < .05
within the dlPFC for the ROI analysis and within the
whole-brain for the exploratory whole-brain analysis. The
minimum cluster size will be determined using AFNI’s
3dClustSim function. The spatial autocorrelation function
(acf) option was used in AFNI’s 3dFWHMx to estimate intrinsic smoothness and 3dClustSim to estimate the probability of false positives [37, 38]. The mean percentage
signal change from dlPFC clusters that pass cluster thresholding will be used as the primary outcome data to test the
hypothesis described in aim 1.
Resting state scan Prior to completing the regulationof-craving task, approximately 10 min of resting state
data will be acquired while participants are instructed to
keep their eyes open and focused on a fixation cross at
the center of the screen. Heart rate and respiration rate
will be collected using Biopac (BIOPAC MP150 Data
Acquisition). This scan will be used in exploratory analyses to examine changes in resting state connectivity
between cognitive control regions and the rest of the
brain following the intervention.
Resting state data preprocessing Freesurfer will be
used to segment gray matter, white matter, and cerebral
spinal fluid. In addition, respiration and heart rate will be
processed using AFNI’s RetroTS. Preprocessing analysis
scripts will be built using afni_restproc.py [39]. Preprocessing will include removing the first four volumes, removing
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any transient signal, slice time correction, and co-registering all functional data to the first volume. Nuisance variables will be measured [i.e., six motion parameters (three
translations and three rotations), average ventricle signal
and average local white matter signal (15-mm spherical
neighborhood, 3dLocalstat)] and removed from the signal
time course using multiple regression. The residual time
course images will then be smoothed with a 6-mm FWHM
Gaussian kernel, resampled to a 2 × 2 × 2 mm grid, and
spatially normalized to Talairach stereotaxic space. In
addition to controlling for six motion parameters, further
motion correction procedures (i.e., scrubbing) will be used
to reduce the possibility of type I errors related to motion
[40, 41]. Time points with greater than 0.3-mm motion will
be censored.
Self-report assessments

Smoking characteristics The Fagerström Test for Nicotine Dependence [42] will assess nicotine dependence.
Items from the COMMIT Smoking Prevalence Survey
[43] will assess smoking history such as tobacco use (cigarettes per day (CPD) and other tobacco use), age when
first smoked, and quitting/relapse history. Because
neural responses may be influenced by motivation to
quit, we will assess this by asking: “How motivated are
you to quit smoking?” on a scale from 0 to 10.
Individual differences in personality, smoking attitudes,
and mood Autonomous regulation for smoking cessation will be assessed using the Treatment Self-Regulation
Questionnaire [44], an established measure of internalized motivation for behavior change. Self-report impulsivity will be measured with the Barratt Impulsivity Scale
(BIS-11) [45] and the UPPS-P Impulsive Behavior Scale
[46]. Sensitivity to reward will be measured with the Sensitivity to Punishment/Sensitivity to Reward Questionnaire
(SPSRQ) [47]. Items from the multidimensional Brief
Wisconsin Inventory of Smoking Dependence Motives [48]
will assess primary and secondary dependence motives.
The Patient Health Questionnaire-9 (PHQ-9) [49],
Generalized Anxiety Disorder-7 scale (GAD-7) [50], and
Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms scale (from the PhenX Toolkit [51]) will assess depression, anxiety, and ADHD symptoms, respectively.
Other tobacco and substance use Participants will answer questions on cannabis addiction, which focuses on the
diagnostic criteria for cannabis use disorder. To create this
measure, we adapted questions from the Yale Food Addiction Scale [52], which assesses multiple aspects of addiction,
such as tolerance, frequency of use, and preoccupation.
Other tobacco and substance use will be characterized using
the following instruments from the PhenX Toolkit [51]: Use
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of Tobacco Products, Substances: 30-day Frequency, Substances: Lifetime Use.

balloons and the total banked money on non-popped trials will be used as primary measures.

Behavioral measures

Impulsive choice A computerized delay discounting
task [61, 62] (E-Prime 3.0) will be used to assess impulsive choice. The delay discounting task asks participants
to choose between hypothetical smaller-sooner and
larger-later rewards across a wide range of delays (1 day
to 25 years). The smaller reward is adjusted after each
choice (up if the participant rejected it on the previous
trial or down if the participant accepted it) and the value
of the smaller reward after five choices is taken as the
indifference point or switch point. Participants will
complete three versions of the task, each with a different
reward type (money, cigarettes, or food) roughly equated
for value. The extent to which each commodity loses
value as a function of time-to-receipt, determined by
mathematical modeling of the discounting curve created
by plotting switch points as a function of delay, will be
the primary measure of impulsivity.

Measures of the demand for cigarettes, executive function/inhibitory control, risk-taking, and impulsive choice
will be administered outside of the scanner to test if
practice leads to behavioral changes.
Demand for cigarettes A cigarette purchase task [53,
54] will be used to measure the demand for cigarettes.
In this task, participants are asked how many cigarettes
they would smoke in a day across a wide range of hypothetical per-cigarette prices ($0.01 to $35). The resulting
data will be modeled to yield a number of economic indicators related to demand including elasticity, intensity,
breakpoint, and maximum expenditure.
Executive function and inhibitory control A Stroop
task and a go/no-go task will be used as measures of executive function/inhibitory control. In the Stroop task [55],
participants are asked to press keyboard buttons corresponding to the font color of neutral words (e.g., “when”
and “and”) and color words (e.g., “blue” and “red”) presented on-screen using the Psychology Experiment Building
Language (PEBL) [56]. In some trials (incongruent trials),
the color words are presented in a mismatching font color
(e.g., the word “yellow” in a green font). In these cases, participants must ignore the semantic content of the word to
get the correct answer. Errors and the response times in
these trials (compared to the congruent trials) will be used
as the primary variables.
In the go/no-go task [57], participants consecutively see
individual letters on a computer monitor. This test was
developed using E-Prime 3.0 (Psychology Software Tools,
Inc., Sharpsburg, PA, USA). Participants are asked to press
a button if and only if a certain sequence of letters occurs
(e.g., “S” followed by “T”). These are considered go trials.
When “S” is followed by any other letter, it is considered a
no-go trial. Several measures will be computed including
the percentage of correct go responses, mean reaction
time of go responses, percentage of false alarms (overall
and just on no-go trials), and impulsivity and inattention
scores as defined by Overtoom et al. [58].
Risk-taking The PEBL version of the balloon analog risk
task [59, 60] will be used to assess risk-taking. Participants will be asked to press a button that pumps up an
on-screen balloon. Every pump is rewarded with a small
amount of virtual money but carries the risk of bursting
the balloon. Participants may choose to bank the money
earned for a balloon at any time, thus ending the trial.
Popping the balloon resets the money counter back to
zero and starts a new trial. The number of popped

Data management

Study data will be collected and managed using REDCap
(Research Electronic Data Capture), which is hosted at the
University of Kansas Medical Center [63]. REDCap is a secure web-based application designed to support data capture for research studies. It provides: (1) an intuitive
interface for validated data entry, (2) an audit trail for
tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads
to common statistical packages, and (4) procedures for
importing data from external sources. All self-report data
will be entered directly into REDCap by participants and
all daily monitoring logs will be double entered. Physical
documents will be kept in a locked cabinet accessible only
by study staff to comply with confidentiality requirements.
MRI data will be sent directly from the scanner to the
Hoglund Brain Imaging Center server, which runs XNAT
1.6.4 [64], an open-source imaging informatics platform
designed to facilitate management of imaging. Task and
resting state fMRI data will be checked by trained research
personnel to ensure the quality of acquired and preprocessed data prior to group analysis. As a relatively
short-term study with minimal participant risks, a data
monitoring committee will not be used. Any adverse
events (although these are anticipated to be minimal) will
be reported to the local institutional review board as per
local standards. The trial will be subject to random auditing per local standards but no auditing by within-study
staff is planned.
Modifications of the protocol

Any modifications to the protocol that may impact on the
conduct of the study, the potential benefits to the patients,
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or patient safety, including changes of study objectives,
study design, population, sample sizes, study procedures,
or significant administrative aspects, will require a formal
amendment to the protocol. Such amendments will be at
the discretion of the principal investigator in consultation
with other key study personnel. Any such major changes
will be communicated to ClinicalTrials.gov.

Discussion
Despite advances in treatments for smoking cessation, most
quit attempts fail and smoking still places an unacceptable
burden on public health. Nonpharmacological treatment is
somewhat effective but the precise mechanism of how it
works remains mostly unknown. Dual models of addiction
suggest that any effective treatment of addiction should target the neural pathways involved in cognitive control [5].
We are testing the overarching hypothesis that explicit cognitive control-related practice related to smoking will increase smokers cognitive control capacity, which will be
reflected in cognitive control-related brain activation.
When complete, this project is expected to achieve
two goals. First, we are beginning the process of linking
treatment research with the extensive work on developing neural models of addiction. The value of neural
models of addiction can only be realized if they are used
to understand and inform treatment approaches. The
dual-system models of addiction suggest that treatments
that enhance cognitive control should help smokers to
quit more successfully. Whether existing treatments
have this effect is unknown. Whether existing treatments
can be optimized or targeted to appropriate individuals
to maximize the neural impact is unknown. Second, establishing important biomarkers of treatment effects
could lead to efficient and powerful ways of pre-testing
or optimizing novel treatments prior to conducting large
expensive randomized clinical trials. This project could
serve as a launching point for many similar experiments
to determine which interventions are worth scaling up
to larger more involved experimental designs.
Trial Status

Recruitment began in December 2016 and is planned to
conclude in June 2019. The current protocol has been approved by the University of Kansas Medical Center Human
Subjects Committee, ID STUDY00004095, version 10.01.
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